APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cancer Biopharmaceuticals

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Cancer Biopharmaceuticals Market Analysis and Forecast 2026-2032

20 December 2025192 pages

Choose your research edition.

Industry ResearchCancer Biopharmaceuticals Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Cancer Biopharmaceuticals Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Cancer Biopharmaceuticals Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cancer Biopharmaceuticals Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Cancer Biopharmaceuticals Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Cancer Biopharmaceuticals market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Cancer Biopharmaceuticals is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Cancer Biopharmaceuticals is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Cancer Biopharmaceuticals is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Cancer Biopharmaceuticals is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Cancer Biopharmaceuticals include Sanofi, Johnson & Johnson, Novartis, Merck, Mylan, Eli Lilly, Pfizer, GlaxoSmithKline and AstraZeneca, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Cancer Biopharmaceuticals, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Cancer Biopharmaceuticals, also provides the revenue of main regions and countries. Of the upcoming market potential for Cancer Biopharmaceuticals, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Cancer Biopharmaceuticals revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Cancer Biopharmaceuticals market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Cancer Biopharmaceuticals revenue, projected growth trends, production technology, application and end-user industry.

Cancer Biopharmaceuticals Segment by Company

Sanofi

Johnson & Johnson

Novartis

Merck

Mylan

Eli Lilly

Pfizer

GlaxoSmithKline

AstraZeneca

LEO Pharma

Elusys Therapeutics

Bristol-Myers Squibb

Boehringer Ingelheim

Alexion Pharmaceuticals

Agios Pharmaceuticals

Cancer Biopharmaceuticals Segment by Type

Biologics

Biosimilars

Cancer Biopharmaceuticals Segment by Application

Liquid Cancers

Solid Cancers

Cancer Biopharmaceuticals Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cancer Biopharmaceuticals market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cancer Biopharmaceuticals and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cancer Biopharmaceuticals.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Cancer Biopharmaceuticals in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Cancer Biopharmaceuticals company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Cancer Biopharmaceuticals revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Cancer Biopharmaceuticals Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Biologics Major Player Table 3. Biosimilars Major Player Table 4. Global Cancer Biopharmaceuticals Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Liquid Cancers Major Player Table 6. Solid Cancers Major Player Table 7. Cancer Biopharmaceuticals Industry Trends Table 8. Cancer Biopharmaceuticals Industry Drivers Table 9. Cancer Biopharmaceuticals Industry Opportunities and Challenges Table 10. Cancer Biopharmaceuticals Industry Restraints Table 11. Global Cancer Biopharmaceuticals Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 12. Global Cancer Biopharmaceuticals Market Size by Region (2021-2026) & (US$ Million) Table 13. Global Cancer Biopharmaceuticals Market Share by Region (2021-2026) Table 14. Global Cancer Biopharmaceuticals Market Size by Region (2027-2032) & (US$ Million) Table 15. Global Cancer Biopharmaceuticals Market Share by Region (2027-2032) Table 16. Global Cancer Biopharmaceuticals Revenue by Players (US$ Million) & (2021-2026) Table 17. Global Cancer Biopharmaceuticals Revenue Market Share by Players (2021-2026) Table 18. Global Cancer Biopharmaceuticals Key Players Ranking, 2024 VS 2025 VS 2026 Table 19. Global Cancer Biopharmaceuticals Key Players Headquarters & Area Served Table 20. Global Cancer Biopharmaceuticals Players, Product Type & Application Table 21. Global Cancer Biopharmaceuticals Players Establishment Date Table 22. Global Players Market Concentration Ratio (CR5 and HHI) Table 23. Global Cancer Biopharmaceuticals by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 24. Global Cancer Biopharmaceuticals Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Cancer Biopharmaceuticals Revenue by Type (2021-2026) & (US$ Million) Table 26. Global Cancer Biopharmaceuticals Revenue by Type (2027-2032) & (US$ Million) Table 27. Global Cancer Biopharmaceuticals Revenue Market Share by Type (2021-2026) Table 28. Global Cancer Biopharmaceuticals Revenue Market Share by Type (2027-2032) Table 29. Global Cancer Biopharmaceuticals Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Cancer Biopharmaceuticals Revenue by Application (2021-2026) & (US$ Million) Table 31. Global Cancer Biopharmaceuticals Revenue by Application (2027-2032) & (US$ Million) Table 32. Global Cancer Biopharmaceuticals Revenue Market Share by Application (2021-2026) Table 33. Global Cancer Biopharmaceuticals Revenue Market Share by Application (2027-2032) Table 34. Sanofi Company Information Table 35. Sanofi Business Overview Table 36. Sanofi Cancer Biopharmaceuticals Revenue and Gross Margin (US$ Million) & (2021-2026) Table 37. Sanofi Cancer Biopharmaceuticals Product Portfolio Table 38. Sanofi Recent Development Table 39. Johnson & Johnson Company Information Table 40. Johnson & Johnson Business Overview Table 41. Johnson & Johnson Cancer Biopharmaceuticals Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Johnson & Johnson Cancer Biopharmaceuticals Product Portfolio Table 43. Johnson & Johnson Recent Development Table 44. Novartis Company Information Table 45. Novartis Business Overview Table 46. Novartis Cancer Biopharmaceuticals Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Novartis Cancer Biopharmaceuticals Product Portfolio Table 48. Novartis Recent Development Table 49. Merck Company Information Table 50. Merck Business Overview Table 51. Merck Cancer Biopharmaceuticals Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. Merck Cancer Biopharmaceuticals Product Portfolio Table 53. Merck Recent Development Table 54. Mylan Company Information Table 55. Mylan Business Overview Table 56. Mylan Cancer Biopharmaceuticals Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. Mylan Cancer Biopharmaceuticals Product Portfolio Table 58. Mylan Recent Development Table 59. Eli Lilly Company Information Table 60. Eli Lilly Business Overview Table 61. Eli Lilly Cancer Biopharmaceuticals Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Eli Lilly Cancer Biopharmaceuticals Product Portfolio Table 63. Eli Lilly Recent Development Table 64. Pfizer Company Information Table 65. Pfizer Business Overview Table 66. Pfizer Cancer Biopharmaceuticals Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. Pfizer Cancer Biopharmaceuticals Product Portfolio Table 68. Pfizer Recent Development Table 69. GlaxoSmithKline Company Information Table 70. GlaxoSmithKline Business Overview Table 71. GlaxoSmithKline Cancer Biopharmaceuticals Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. GlaxoSmithKline Cancer Biopharmaceuticals Product Portfolio Table 73. GlaxoSmithKline Recent Development Table 74. AstraZeneca Company Information Table 75. AstraZeneca Business Overview Table 76. AstraZeneca Cancer Biopharmaceuticals Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. AstraZeneca Cancer Biopharmaceuticals Product Portfolio Table 78. AstraZeneca Recent Development Table 79. LEO Pharma Company Information Table 80. LEO Pharma Business Overview Table 81. LEO Pharma Cancer Biopharmaceuticals Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. LEO Pharma Cancer Biopharmaceuticals Product Portfolio Table 83. LEO Pharma Recent Development Table 84. Elusys Therapeutics Company Information Table 85. Elusys Therapeutics Business Overview Table 86. Elusys Therapeutics Cancer Biopharmaceuticals Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 87. Elusys Therapeutics Cancer Biopharmaceuticals Product Portfolio Table 88. Elusys Therapeutics Recent Development Table 89. Bristol-Myers Squibb Company Information Table 90. Bristol-Myers Squibb Business Overview Table 91. Bristol-Myers Squibb Cancer Biopharmaceuticals Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. Bristol-Myers Squibb Cancer Biopharmaceuticals Product Portfolio Table 93. Bristol-Myers Squibb Recent Development Table 94. Boehringer Ingelheim Company Information Table 95. Boehringer Ingelheim Business Overview Table 96. Boehringer Ingelheim Cancer Biopharmaceuticals Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. Boehringer Ingelheim Cancer Biopharmaceuticals Product Portfolio Table 98. Boehringer Ingelheim Recent Development Table 99. Alexion Pharmaceuticals Company Information Table 100. Alexion Pharmaceuticals Business Overview Table 101. Alexion Pharmaceuticals Cancer Biopharmaceuticals Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. Alexion Pharmaceuticals Cancer Biopharmaceuticals Product Portfolio Table 103. Alexion Pharmaceuticals Recent Development Table 104. Agios Pharmaceuticals Company Information Table 105. Agios Pharmaceuticals Business Overview Table 106. Agios Pharmaceuticals Cancer Biopharmaceuticals Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 107. Agios Pharmaceuticals Cancer Biopharmaceuticals Product Portfolio Table 108. Agios Pharmaceuticals Recent Development Table 109. North America Cancer Biopharmaceuticals Revenue by Type (2021-2026) & (US$ Million) Table 110. North America Cancer Biopharmaceuticals Revenue by Type (2027-2032) & (US$ Million) Table 111. North America Cancer Biopharmaceuticals Revenue by Application (2021-2026) & (US$ Million) Table 112. North America Cancer Biopharmaceuticals Revenue by Application (2027-2032) & (US$ Million) Table 113. North America Cancer Biopharmaceuticals Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 114. North America Cancer Biopharmaceuticals Revenue by Country (2021-2026) & (US$ Million) Table 115. North America Cancer Biopharmaceuticals Revenue by Country (US$ Million) & (2027-2032) Table 116. Europe Cancer Biopharmaceuticals Revenue by Type (2021-2026) & (US$ Million) Table 117. Europe Cancer Biopharmaceuticals Revenue by Type (2027-2032) & (US$ Million) Table 118. Europe Cancer Biopharmaceuticals Revenue by Application (2021-2026) & (US$ Million) Table 119. Europe Cancer Biopharmaceuticals Revenue by Application (2027-2032) & (US$ Million) Table 120. Europe Cancer Biopharmaceuticals Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 121. Europe Cancer Biopharmaceuticals Revenue by Country (2021-2026) & (US$ Million) Table 122. Europe Cancer Biopharmaceuticals Revenue by Country (US$ Million) & (2027-2032) Table 123. China Cancer Biopharmaceuticals Revenue by Type (2021-2026) & (US$ Million) Table 124. China Cancer Biopharmaceuticals Revenue by Type (2027-2032) & (US$ Million) Table 125. China Cancer Biopharmaceuticals Revenue by Application (2021-2026) & (US$ Million) Table 126. China Cancer Biopharmaceuticals Revenue by Application (2027-2032) & (US$ Million) Table 127. Asia Cancer Biopharmaceuticals Revenue by Type (2021-2026) & (US$ Million) Table 128. Asia Cancer Biopharmaceuticals Revenue by Type (2027-2032) & (US$ Million) Table 129. Asia Cancer Biopharmaceuticals Revenue by Application (2021-2026) & (US$ Million) Table 130. Asia Cancer Biopharmaceuticals Revenue by Application (2027-2032) & (US$ Million) Table 131. Asia Cancer Biopharmaceuticals Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 132. Asia Cancer Biopharmaceuticals Revenue by Region (US$ Million) & (2021-2026) Table 133. Asia Cancer Biopharmaceuticals Revenue by Region (US$ Million) & (2027-2032) Table 134. SAMEA Cancer Biopharmaceuticals Revenue by Type (2021-2026) & (US$ Million) Table 135. SAMEA Cancer Biopharmaceuticals Revenue by Type (2027-2032) & (US$ Million) Table 136. SAMEA Cancer Biopharmaceuticals Revenue by Application (2021-2026) & (US$ Million) Table 137. SAMEA Cancer Biopharmaceuticals Revenue by Application (2027-2032) & (US$ Million) Table 138. SAMEA Cancer Biopharmaceuticals Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 139. SAMEA Cancer Biopharmaceuticals Revenue by Country (2021-2026) & (US$ Million) Table 140. SAMEA Cancer Biopharmaceuticals Revenue by Country (US$ Million) & (2027-2032) Table 141. Research Programs/Design for This Report Table 142. Authors List of This Report Table 143. Secondary Sources Table 144. Primary Sources List of Figures Figure 1. Cancer Biopharmaceuticals Image Figure 2. Global Cancer Biopharmaceuticals Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cancer Biopharmaceuticals Market Size Share 2021 VS 2025 VS 2032 Figure 4. Biologics Image Figure 5. Biosimilars Image Figure 6. Global Cancer Biopharmaceuticals Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Cancer Biopharmaceuticals Market Size Share 2021 VS 2025 VS 2032 Figure 8. Liquid Cancers Image Figure 9. Solid Cancers Image Figure 10. Global Cancer Biopharmaceuticals Market Size (US$ Million) & (2021-2032) Figure 11. Global Cancer Biopharmaceuticals Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Cancer Biopharmaceuticals Market Share by Region: 2021 VS 2025 VS 2032 Figure 13. Global Cancer Biopharmaceuticals Players Revenue Share Top 10 and Top 5 in 2025 Figure 14. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 15. Global Cancer Biopharmaceuticals Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Cancer Biopharmaceuticals Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Cancer Biopharmaceuticals Revenue Market Share by Type (2021-2032) Figure 18. Global Cancer Biopharmaceuticals Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Cancer Biopharmaceuticals Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 20. Global Cancer Biopharmaceuticals Revenue Market Share by Application (2021-2032) Figure 21. North America Cancer Biopharmaceuticals Revenue YoY Growth (2021-2032) & (US$ Million) Figure 22. North America Cancer Biopharmaceuticals Revenue Share by Type (2021-2032) Figure 23. North America Cancer Biopharmaceuticals Revenue Share by Application (2021-2032) Figure 24. North America Cancer Biopharmaceuticals Revenue Share by Country (2021-2032) Figure 25. United States Cancer Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 26. Canada Cancer Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Mexico Cancer Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Europe Cancer Biopharmaceuticals Revenue YoY Growth (2021-2032) & (US$ Million) Figure 29. Europe Cancer Biopharmaceuticals Revenue Share by Type (2021-2032) Figure 30. Europe Cancer Biopharmaceuticals Revenue Share by Application (2021-2032) Figure 31. Europe Cancer Biopharmaceuticals Revenue Share by Country (2021-2032) Figure 32. Germany Cancer Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. France Cancer Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. U.K. Cancer Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. Italy Cancer Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Spain Cancer Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Russia Cancer Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Netherlands Cancer Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Nordic Countries Cancer Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. China Cancer Biopharmaceuticals Revenue YoY Growth (2021-2032) & (US$ Million) Figure 41. China Cancer Biopharmaceuticals Revenue Share by Type (2021-2032) Figure 42. China Cancer Biopharmaceuticals Revenue Share by Application (2021-2032) Figure 43. Asia Cancer Biopharmaceuticals Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. Asia Cancer Biopharmaceuticals Revenue Share by Type (2021-2032) Figure 45. Asia Cancer Biopharmaceuticals Revenue Share by Application (2021-2032) Figure 46. Asia Cancer Biopharmaceuticals Revenue Share by Region (2021-2032) Figure 47. Japan Cancer Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 48. South Korea Cancer Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. India Cancer Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. Australia Cancer Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Taiwan Cancer Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Southeast Asia Cancer Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. SAMEA Cancer Biopharmaceuticals Revenue YoY Growth (2021-2032) & (US$ Million) Figure 54. SAMEA Cancer Biopharmaceuticals Revenue Share by Type (2021-2032) Figure 55. SAMEA Cancer Biopharmaceuticals Revenue Share by Application (2021-2032) Figure 56. SAMEA Cancer Biopharmaceuticals Revenue Share by Country (2021-2032) Figure 57. Brazil Cancer Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Argentina Cancer Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Chile Cancer Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Colombia Cancer Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Peru Cancer Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Saudi Arabia Cancer Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Israel Cancer Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. UAE Cancer Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Turkey Cancer Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Iran Cancer Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Egypt Cancer Biopharmaceuticals Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Years Considered Figure 69. Research Process Figure 70. Key Executives Interviewed

Scope & coverage.

Types
  • Biologics
  • Biosimilars
Applications
  • Liquid Cancers
  • Solid Cancers
Companies covered
  • Sanofi
  • Johnson & Johnson
  • Novartis
  • Merck
  • Mylan
  • Eli Lilly
  • Pfizer
  • GlaxoSmithKline
  • AstraZeneca
  • LEO Pharma
  • Elusys Therapeutics
  • Bristol-Myers Squibb
  • Boehringer Ingelheim
  • Alexion Pharmaceuticals
  • Agios Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Cancer Biopharmaceuticals Market by Type
  3. 1.2.1 Global Cancer Biopharmaceuticals Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Biologics
  5. 1.2.3 Biosimilars
  6. 1.3 Cancer Biopharmaceuticals Market by Application
  7. 1.3.1 Global Cancer Biopharmaceuticals Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Liquid Cancers
  9. 1.3.3 Solid Cancers
  10. 1.4 Assumptions and Limitations
  11. 1.5 Study Goals and Objectives
2 Cancer Biopharmaceuticals Market Dynamics
  1. 2.1 Cancer Biopharmaceuticals Industry Trends
  2. 2.2 Cancer Biopharmaceuticals Industry Drivers
  3. 2.3 Cancer Biopharmaceuticals Industry Opportunities and Challenges
  4. 2.4 Cancer Biopharmaceuticals Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Cancer Biopharmaceuticals Market Perspective (2021-2032)
  2. 3.2 Global Cancer Biopharmaceuticals Growth Trends by Region
  3. 3.2.1 Global Cancer Biopharmaceuticals Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Cancer Biopharmaceuticals Market Size by Region (2021-2026)
  5. 3.2.3 Global Cancer Biopharmaceuticals Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Cancer Biopharmaceuticals Revenue by Players
  2. 4.1.1 Global Cancer Biopharmaceuticals Revenue by Players (2021-2026)
  3. 4.1.2 Global Cancer Biopharmaceuticals Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Cancer Biopharmaceuticals Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Cancer Biopharmaceuticals Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Cancer Biopharmaceuticals Key Players Headquarters & Area Served
  7. 4.4 Global Cancer Biopharmaceuticals Players, Product Type & Application
  8. 4.5 Global Cancer Biopharmaceuticals Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Cancer Biopharmaceuticals Market CR5 and HHI
  11. 4.6.3 2025 Cancer Biopharmaceuticals Tier 1, Tier 2, and Tier 3
5 Cancer Biopharmaceuticals Market Size by Type
  1. 5.1 Global Cancer Biopharmaceuticals Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Cancer Biopharmaceuticals Revenue by Type (2021-2032)
  3. 5.3 Global Cancer Biopharmaceuticals Revenue Market Share by Type (2021-2032)
6 Cancer Biopharmaceuticals Market Size by Application
  1. 6.1 Global Cancer Biopharmaceuticals Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Cancer Biopharmaceuticals Revenue by Application (2021-2032)
  3. 6.3 Global Cancer Biopharmaceuticals Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Sanofi
  2. 7.1.1 Sanofi Company Information
  3. 7.1.2 Sanofi Business Overview
  4. 7.1.3 Sanofi Cancer Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Sanofi Cancer Biopharmaceuticals Product Portfolio
  6. 7.1.5 Sanofi Recent Developments
  7. 7.2 Johnson & Johnson
  8. 7.2.1 Johnson & Johnson Company Information
  9. 7.2.2 Johnson & Johnson Business Overview
  10. 7.2.3 Johnson & Johnson Cancer Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Johnson & Johnson Cancer Biopharmaceuticals Product Portfolio
  12. 7.2.5 Johnson & Johnson Recent Developments
  13. 7.3 Novartis
  14. 7.3.1 Novartis Company Information
  15. 7.3.2 Novartis Business Overview
  16. 7.3.3 Novartis Cancer Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Novartis Cancer Biopharmaceuticals Product Portfolio
  18. 7.3.5 Novartis Recent Developments
  19. 7.4 Merck
  20. 7.4.1 Merck Company Information
  21. 7.4.2 Merck Business Overview
  22. 7.4.3 Merck Cancer Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Merck Cancer Biopharmaceuticals Product Portfolio
  24. 7.4.5 Merck Recent Developments
  25. 7.5 Mylan
  26. 7.5.1 Mylan Company Information
  27. 7.5.2 Mylan Business Overview
  28. 7.5.3 Mylan Cancer Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Mylan Cancer Biopharmaceuticals Product Portfolio
  30. 7.5.5 Mylan Recent Developments
  31. 7.6 Eli Lilly
  32. 7.6.1 Eli Lilly Company Information
  33. 7.6.2 Eli Lilly Business Overview
  34. 7.6.3 Eli Lilly Cancer Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Eli Lilly Cancer Biopharmaceuticals Product Portfolio
  36. 7.6.5 Eli Lilly Recent Developments
  37. 7.7 Pfizer
  38. 7.7.1 Pfizer Company Information
  39. 7.7.2 Pfizer Business Overview
  40. 7.7.3 Pfizer Cancer Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Pfizer Cancer Biopharmaceuticals Product Portfolio
  42. 7.7.5 Pfizer Recent Developments
  43. 7.8 GlaxoSmithKline
  44. 7.8.1 GlaxoSmithKline Company Information
  45. 7.8.2 GlaxoSmithKline Business Overview
  46. 7.8.3 GlaxoSmithKline Cancer Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  47. 7.8.4 GlaxoSmithKline Cancer Biopharmaceuticals Product Portfolio
  48. 7.8.5 GlaxoSmithKline Recent Developments
  49. 7.9 AstraZeneca
  50. 7.9.1 AstraZeneca Company Information
  51. 7.9.2 AstraZeneca Business Overview
  52. 7.9.3 AstraZeneca Cancer Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  53. 7.9.4 AstraZeneca Cancer Biopharmaceuticals Product Portfolio
  54. 7.9.5 AstraZeneca Recent Developments
  55. 7.10 LEO Pharma
  56. 7.10.1 LEO Pharma Company Information
  57. 7.10.2 LEO Pharma Business Overview
  58. 7.10.3 LEO Pharma Cancer Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  59. 7.10.4 LEO Pharma Cancer Biopharmaceuticals Product Portfolio
  60. 7.10.5 LEO Pharma Recent Developments
  61. 7.11 Elusys Therapeutics
  62. 7.11.1 Elusys Therapeutics Company Information
  63. 7.11.2 Elusys Therapeutics Business Overview
  64. 7.11.3 Elusys Therapeutics Cancer Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Elusys Therapeutics Cancer Biopharmaceuticals Product Portfolio
  66. 7.11.5 Elusys Therapeutics Recent Developments
  67. 7.12 Bristol-Myers Squibb
  68. 7.12.1 Bristol-Myers Squibb Company Information
  69. 7.12.2 Bristol-Myers Squibb Business Overview
  70. 7.12.3 Bristol-Myers Squibb Cancer Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Bristol-Myers Squibb Cancer Biopharmaceuticals Product Portfolio
  72. 7.12.5 Bristol-Myers Squibb Recent Developments
  73. 7.13 Boehringer Ingelheim
  74. 7.13.1 Boehringer Ingelheim Company Information
  75. 7.13.2 Boehringer Ingelheim Business Overview
  76. 7.13.3 Boehringer Ingelheim Cancer Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Boehringer Ingelheim Cancer Biopharmaceuticals Product Portfolio
  78. 7.13.5 Boehringer Ingelheim Recent Developments
  79. 7.14 Alexion Pharmaceuticals
  80. 7.14.1 Alexion Pharmaceuticals Company Information
  81. 7.14.2 Alexion Pharmaceuticals Business Overview
  82. 7.14.3 Alexion Pharmaceuticals Cancer Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Alexion Pharmaceuticals Cancer Biopharmaceuticals Product Portfolio
  84. 7.14.5 Alexion Pharmaceuticals Recent Developments
  85. 7.15 Agios Pharmaceuticals
  86. 7.15.1 Agios Pharmaceuticals Company Information
  87. 7.15.2 Agios Pharmaceuticals Business Overview
  88. 7.15.3 Agios Pharmaceuticals Cancer Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Agios Pharmaceuticals Cancer Biopharmaceuticals Product Portfolio
  90. 7.15.5 Agios Pharmaceuticals Recent Developments
8 North America
  1. 8.1 North America Cancer Biopharmaceuticals Revenue (2021-2032)
  2. 8.2 North America Cancer Biopharmaceuticals Revenue by Type (2021-2032)
  3. 8.2.1 North America Cancer Biopharmaceuticals Revenue by Type (2021-2026)
  4. 8.2.2 North America Cancer Biopharmaceuticals Revenue by Type (2027-2032)
  5. 8.3 North America Cancer Biopharmaceuticals Revenue Share by Type (2021-2032)
  6. 8.4 North America Cancer Biopharmaceuticals Revenue by Application (2021-2032)
  7. 8.4.1 North America Cancer Biopharmaceuticals Revenue by Application (2021-2026)
  8. 8.4.2 North America Cancer Biopharmaceuticals Revenue by Application (2027-2032)
  9. 8.5 North America Cancer Biopharmaceuticals Revenue Share by Application (2021-2032)
  10. 8.6 North America Cancer Biopharmaceuticals Revenue by Country
  11. 8.6.1 North America Cancer Biopharmaceuticals Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Cancer Biopharmaceuticals Revenue by Country (2021-2026)
  13. 8.6.3 North America Cancer Biopharmaceuticals Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Cancer Biopharmaceuticals Revenue (2021-2032)
  2. 9.2 Europe Cancer Biopharmaceuticals Revenue by Type (2021-2032)
  3. 9.2.1 Europe Cancer Biopharmaceuticals Revenue by Type (2021-2026)
  4. 9.2.2 Europe Cancer Biopharmaceuticals Revenue by Type (2027-2032)
  5. 9.3 Europe Cancer Biopharmaceuticals Revenue Share by Type (2021-2032)
  6. 9.4 Europe Cancer Biopharmaceuticals Revenue by Application (2021-2032)
  7. 9.4.1 Europe Cancer Biopharmaceuticals Revenue by Application (2021-2026)
  8. 9.4.2 Europe Cancer Biopharmaceuticals Revenue by Application (2027-2032)
  9. 9.5 Europe Cancer Biopharmaceuticals Revenue Share by Application (2021-2032)
  10. 9.6 Europe Cancer Biopharmaceuticals Revenue by Country
  11. 9.6.1 Europe Cancer Biopharmaceuticals Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Cancer Biopharmaceuticals Revenue by Country (2021-2026)
  13. 9.6.3 Europe Cancer Biopharmaceuticals Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Cancer Biopharmaceuticals Revenue (2021-2032)
  2. 10.2 China Cancer Biopharmaceuticals Revenue by Type (2021-2032)
  3. 10.2.1 China Cancer Biopharmaceuticals Revenue by Type (2021-2026)
  4. 10.2.2 China Cancer Biopharmaceuticals Revenue by Type (2027-2032)
  5. 10.3 China Cancer Biopharmaceuticals Revenue Share by Type (2021-2032)
  6. 10.4 China Cancer Biopharmaceuticals Revenue by Application (2021-2032)
  7. 10.4.1 China Cancer Biopharmaceuticals Revenue by Application (2021-2026)
  8. 10.4.2 China Cancer Biopharmaceuticals Revenue by Application (2027-2032)
  9. 10.5 China Cancer Biopharmaceuticals Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Cancer Biopharmaceuticals Revenue (2021-2032)
  2. 11.2 Asia Cancer Biopharmaceuticals Revenue by Type (2021-2032)
  3. 11.2.1 Asia Cancer Biopharmaceuticals Revenue by Type (2021-2026)
  4. 11.2.2 Asia Cancer Biopharmaceuticals Revenue by Type (2027-2032)
  5. 11.3 Asia Cancer Biopharmaceuticals Revenue Share by Type (2021-2032)
  6. 11.4 Asia Cancer Biopharmaceuticals Revenue by Application (2021-2032)
  7. 11.4.1 Asia Cancer Biopharmaceuticals Revenue by Application (2021-2026)
  8. 11.4.2 Asia Cancer Biopharmaceuticals Revenue by Application (2027-2032)
  9. 11.5 Asia Cancer Biopharmaceuticals Revenue Share by Application (2021-2032)
  10. 11.6 Asia Cancer Biopharmaceuticals Revenue by Country
  11. 11.6.1 Asia Cancer Biopharmaceuticals Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Cancer Biopharmaceuticals Revenue by Country (2021-2026)
  13. 11.6.3 Asia Cancer Biopharmaceuticals Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Cancer Biopharmaceuticals Revenue (2021-2032)
  2. 12.2 SAMEA Cancer Biopharmaceuticals Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Cancer Biopharmaceuticals Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Cancer Biopharmaceuticals Revenue by Type (2027-2032)
  5. 12.3 SAMEA Cancer Biopharmaceuticals Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Cancer Biopharmaceuticals Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Cancer Biopharmaceuticals Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Cancer Biopharmaceuticals Revenue by Application (2027-2032)
  9. 12.5 SAMEA Cancer Biopharmaceuticals Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Cancer Biopharmaceuticals Revenue by Country
  11. 12.6.1 SAMEA Cancer Biopharmaceuticals Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Cancer Biopharmaceuticals Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Cancer Biopharmaceuticals Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst